LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint

Shares of medical device company LivaNova (LIVN) are up over 11% or $5.60 per share in late trading on Wednesday after earlier in the day announcing its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation, has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. “This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint,” noted the company in the release… Other companies in the sleep apnea space include ResMed (RMD), Inspire Medical (INSP), and Vivos Therapeutics (VVOS).